Applied Therapeutics (NASDAQ:APLT) Shares Down 3.3%

Applied Therapeutics, Inc. (NASDAQ:APLT)’s share price fell 3.3% on Wednesday . The stock traded as low as $4.98 and last traded at $4.98. 61,282 shares changed hands during trading, a decline of 97% from the average session volume of 1,982,179 shares. The stock had previously closed at $5.15.

Analyst Ratings Changes

Several brokerages have recently weighed in on APLT. Leerink Partnrs reiterated an “outperform” rating on shares of Applied Therapeutics in a research note on Thursday, February 22nd. UBS Group lifted their price target on shares of Applied Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Royal Bank of Canada restated an “outperform” rating and set a $12.00 price objective on shares of Applied Therapeutics in a research report on Thursday, April 11th. SVB Leerink began coverage on shares of Applied Therapeutics in a research report on Thursday, February 22nd. They set an “outperform” rating and a $12.00 price objective on the stock. Finally, Citigroup raised their price objective on shares of Applied Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, February 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Applied Therapeutics currently has an average rating of “Buy” and an average target price of $11.60.

Applied Therapeutics Stock Performance

The company has a market capitalization of $501.92 million, a P/E ratio of -3.51 and a beta of 1.81. The business’s fifty day simple moving average is $5.75 and its 200-day simple moving average is $3.69.

Applied Therapeutics (NASDAQ:APLT) last announced its quarterly earnings results on Wednesday, March 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.18). The business had revenue of ($0.67) million for the quarter. As a group, analysts forecast that Applied Therapeutics, Inc. will post -0.53 EPS for the current year.

Insider Buying and Selling at Applied Therapeutics

In other Applied Therapeutics news, CFO Leslie D. Funtleyder sold 28,727 shares of Applied Therapeutics stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $5.39, for a total value of $154,838.53. Following the sale, the chief financial officer now directly owns 308,421 shares in the company, valued at approximately $1,662,389.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Riccardo Perfetti sold 110,804 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $5.39, for a total value of $597,233.56. Following the sale, the insider now directly owns 1,031,537 shares in the company, valued at approximately $5,559,984.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Leslie D. Funtleyder sold 28,727 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $5.39, for a total transaction of $154,838.53. Following the completion of the sale, the chief financial officer now owns 308,421 shares in the company, valued at $1,662,389.19. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 458,104 shares of company stock worth $2,469,181. Insiders own 19.10% of the company’s stock.

Institutional Trading of Applied Therapeutics

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Applied Therapeutics by 126.1% in the 4th quarter. Vanguard Group Inc. now owns 3,230,481 shares of the company’s stock worth $10,822,000 after buying an additional 1,801,827 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Applied Therapeutics in the 4th quarter worth about $56,000. Opaleye Management Inc. increased its holdings in shares of Applied Therapeutics by 22.3% in the 4th quarter. Opaleye Management Inc. now owns 1,092,500 shares of the company’s stock worth $3,660,000 after buying an additional 199,500 shares during the last quarter. Bridgeway Capital Management LLC increased its holdings in shares of Applied Therapeutics by 34.8% in the 4th quarter. Bridgeway Capital Management LLC now owns 193,800 shares of the company’s stock worth $649,000 after buying an additional 50,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Applied Therapeutics in the 4th quarter worth about $36,000. 98.31% of the stock is currently owned by institutional investors.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.